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Figure 2. Fold-change in pCCR5 on CD8 T-cells in response to CCL4 stimula-
tion with or without MVC
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S333unstimulated control. The surface expression of CCR5 was
measured separately by ﬂow cytometry.
Results: Twenty-four reduced-intensity alloSCT recipients
received MVC 300 mg b.i.d. orally from day -3 to day +90 on
an ongoing phase II study. Recipient bloodwas tested on days
-6 (beforeMVC), 0 and 14, and donor bloodwas tested on day
0. We observed signiﬁcant variability in surface CCR5
expression on T-cells in donors (range 0e9%) and recipients
(range 0e49%). Recipient surface CCR5 expression increased
from d-6 to d0 on both CD4 (mean 3.6 to 7.3%, p¼0.005) and
CD8 (mean 13.5 to 30.6%, p¼0.005) T-cells, consistent with
blockade of receptor internalization.
CD8 T-cell pCCR5 levels increased in response to CCL4
stimulation on d -6 (p¼0.01) and decreased in response to
MVC (p¼0.002), compared to unstimulated blood (Fig. 2). A
decrease in pCCR5 levels in response to MVC was observed
evenwithout CCL4 stimulation, reﬂecting loss of background
CCR5 activity (p¼0.0002). In contrast, d0 pCCR5 levels failed
to increase in response to CCL4 (p¼0.32), nor did they
decrease in response to additional MVC (p¼0.13), mirroring
effective in vivo blockade of CCR5.
The magnitude of increase in CD8 T-cell pCCR5 levels in
response to CCL4 stimulation on d-6 correlated with CCR5
surface expression (r¼0.55, p¼0.02). The same was true of
CD4 T-cells (r¼0.76, p¼0.0004). On d0, however, the ability
to stimulate CCR5 inversely correlated with CCR5
surface expression for both CD8 (r¼-0.46, p¼0.04) and CD4
(r¼-0.62, p¼0.004), suggesting that greater CCR5 surface
upregulation may serve as an indicator for complete re-
ceptor blockade.
Conclusions: Intracellular phosphorylation of CCR5 in
response to stimulation is efﬁciently blocked by MVC in pa-
tients undergoing alloSCT, as measured by a novel phos-
phoﬂow assay. Upregulation of surface CCR5 may indicate
effective CCR5 blockade and should be explored as a
biomarker for drug response.484
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Cellular Therapy, The University of Texas MD Anderson Cancer
Center, Houston, TXCD1d-restricted invariant Natural Killer (iNK) T cells are rare
but powerful regulatory T cells that can produce a large
amount of both inﬂammatory (Th-1 type) and regulatory
(Th-2 type) cytokines upon activation. Therefore, they can
potentially shape subsequent adaptive immune responses
towards inﬂammation or immune tolerance. Unlike the other
regulatory immune cells, iNK T cells are heterogeneous in
phenotype (CD4+ vs CD4- vs CD8a+), and display a spectrum
of function ranging from regulatory to inﬂammatory re-
sponses. Given the potential regulatory function, iNKT cells
are thought to play a role in preventing Graft Versus Host
Disease (GVHD) in allogeneic stem cell transplant (SCT). Yet,
the precisemechanism of immune regulation by iNKTcells in
allogeneic SCT setting has not been clearly elucidated. As the
cord blood stem cell transplantation is known to have a
reduced incidence of GVHD as compared to matched adult
donor allogeneic SCT, we hypothesize that iNK T cells in cord
blood possess the regulatory phenotype and function as
compared to those in healthy adults, thus play a role in
preventing GVHD. To test this hypothesis, we ﬁrst charac-
terized the phenotype of iNK T cells from 25 cord blood and
25 peripheral blood of healthy adults using multi-color Flow
Cytometry.We found that iNK Tcells were present in variable
frequencies ranging from 0.01% to 2% of T cells from healthy
adults but rather in similar frequencies around 0.1% of T cells
from cord blood. Interestingly, the extremely high percent-
age of CD4+CD25+CD161- iNK T cells was present in cord
blood, while iNK T cells from healthy adults were heteroge-
neous in phenotype with a trend towards higher percentage
of CD4-CD25-CD161+ iNK T cells. Next, we investigated
whether CD4+CD25+ iNK T cells from cord blood indeed
display regulatory property, and assessed cytokine produc-
tion proﬁle of ex vivo expanded polyclonal iNK T cells stim-
ulated by autologous or allogeneic dendritic cells in the
presence of alpha-GalCer, agonist glycolipid antigen. We
found that the iNK T cells from cord blood preferentially
produced Th-2 type cytokines (GM-CSF, IL-13, IL-4, IL-5) as
compared to iNK T cells from healthy adults. Lastly, poly-
clonal iNK T cells showed signiﬁcant cytokine production to
autologous or allogeneic dendritic cells in the absence of
alpha-GalCer, suggesting that iNK T cells can be activated by
endogenous glycolipid antigens in physiologic condition. In
summary, we demonstrated that CD4+CD25+CD161-iNK T
cells were enriched in cord blood, and indeed displayed
regulatory property. Our results sugest that CD4+CD25+ iNK
T cells may play role in immunoregulation to prevent GVHD
via regulatory function.485
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Background and Objective: Antineoplastic MEK inhibitors
have immunomodulatory activity. MEK inhibition selectively
suppresses naïve/central memory T cells while sparing
effector memory T cells, and delays the onset of murine
GVHD (Shindo, Kim, Komanduri et al. Blood 2013). We
investigated whether MEK inhibition selectively suppresses
Figure 1. Trametinib suppresses GVHD in the BDF1 model
Figure 3. Trametinib spares GVT effects
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versus-Tumor (GVT) effects are spared.
Methods: We adopted three murine BMT models: 1)
Transplantation of B6-BM and T cells into B6D2F1 mice
(MHC-haploidentical BDF1 model); 2) Transplantation of
B10.D2-BM and T cells into Balb/c mice (Skin GVHD and
immune alopecia model); 3) Transfusion of P815 cells in the
BDF1model (GVTmodel). Various doses of the MEK inhibitor
trametinib (or vehicle) were orally given.
Results: 15-days administration of trametinib signiﬁcantly
prolonged survival of GVHD mice (Fig. 1), and suppressed
GVHD symptoms and pathology in the gut and skin. BDF1-
GVHD mice revealed increased phosphorylation of ERK in
peripheral blood CD4 and CD8 T cells, which was suppressed
by trametinib (Fig. 2). Trametinib also suppressed expansion
and functional differentiation of donor T cells in vivo.
Although high-dose trametinib (1.0 mg/kg/day) exerted
toxicity, low-dose trametinib (0.1-0.3 mg/kg/day) was toler-
able while still suppressing GVHD. Notably, in the GVT
model, trametinib did not shorten survival of P815- and T
cell-transplanted mice, indicating that it does not suppressFigure 2. Peripheral blood T cells of BDF1-GVHD mice show increaseGVT effects (Fig. 3). Furthermore, trametinib therapy did not
interfere with engraftment nor expansion of Foxp3+ regula-
tory T cells (data not shown).
Conclusions: These results conﬁrmed that trametinib
selectively suppresses GVHD-inducing T cells while sparing
tumor-speciﬁc T cells and other cell subsets in vivo. Given the
demonstrated safety of trametinib in clinical trials of mela-
noma, MEK inhibition may be a promising candidate for
translational studies aimed at preventing or treating GVHD
after allogeneic transplantation.
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